CNTA
HealthcareCentessa Pharmaceuticals plc
$23.02
$-0.67 (-2.83%)
Jan 5, 2026
Price History (1Y)
Analysis
Centessa Pharmaceuticals plc is a biotechnology company in the healthcare sector. With a market capitalization of $3.36B and 114 employees, it operates on a relatively large scale. The company's financial health indicates significant net losses, with a net income of -$242,698,000 over the trailing twelve months (TTM). This is accompanied by negative EBITDA of -$213,490,000 and free cash flow of -$116,738,248. However, it has a substantial cash reserve of $246.21M to support operations, offsetting its debt of $118.26M. Centessa Pharmaceuticals plc's valuation metrics include a forward price-to-earnings (P/E) ratio of -13.99 and an enterprise value-to-EBITDA (EV/EBITDA) ratio of -14.32, indicating significant undervaluation. The company has a high price-to-sales ratio of 224.18, suggesting a premium valuation based on revenue. Its operating margin stands at -1425.3%, highlighting the magnitude of its losses.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Visit website →Key Statistics
- Market Cap
- $3.36B
- P/E Ratio
- N/A
- 52-Week High
- $30.58
- 52-Week Low
- $9.60
- Avg Volume
- 1.52M
- Beta
- 1.57
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United Kingdom
- Employees
- 114